| Current Price | $10.11 | Mkt Cap | $770.5M |
|---|---|---|---|
| Open | $9.83 | P/E Ratio | 0.00 |
| Prev. Close | $9.73 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $9.73 - $10.34 | Volume | 87,754 |
| 52-Wk Range | $9.50 - $20.84 | Avg. Daily Vol. |
| Current Price | $10.11 | Mkt Cap | $770.5M |
|---|---|---|---|
| Open | $9.83 | P/E Ratio | 0.00 |
| Prev. Close | $9.73 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $9.73 - $10.34 | Volume | 87,754 |
| 52-Wk Range | $9.50 - $20.84 | Avg. Daily Vol. |
The best Bull and Bear pitches based on recency and number of recommendations.
Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about CLLS.
Recs
shanelofgren
(31.35)
Submitted: 1/2/2019 1:01:17 PM :
Start Price:
$17.02
NASDAQ:CLLS Score:
-59.98
Renewing pick: bet on allogeneic CAR-T, specifically their partnership with Allogen and their IP portfolio of technologies to KO the TRAC, B2M, and other key genes for allogeneic T cells. Some concerns about the quality of their clinical results suggesting that allogeneic CAR-T may be less efficacious, but upside in reduced time to dose, lot consistency, potential for repeat dosing, etc. I believe offer a higher clinical ceiling once optimal protocol (ie, always inclusion of anti CD52) is determined.
Recs
zzlangerhans
(99.81)
Submitted: 3/28/2015 4:23:27 AM :
Start Price:
$36.00
NASDAQ:CLLS Score:
-117.30
Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting European stocks in hot sectors before the rest of the market catches on and bids them up. In the case of Cellectis it's CAR-T. The potential advantage of Cellectis is that they are generating an allogeneic product that could be marketed "off-the-shelf" unlike the autologous therapeis being developed by Juno and Kite in the US. Cellectis hasn't even filed an IND for any of their CAR-T therapeutics so naturally they fall well into the speculative range of the biotech spectrum. Nevertheless, it's the hottest area in biotech right now so expect a lot of buoyancy in the segment until we see the first major setback or trial failure. We've built up quite a cushion of profits trading Cellectis so I imagine we'll continue to try and milk this cow a while longer.
Find the members with the highest scoring picks in CLLS.
allforone (24.81) Score: +39.40
The Score Leader is the player with the highest score across all their picks in CLLS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| NextGenStock | < 20 | 9/11/2019 |
|
5Y | $12.41 | -18.53% | -0.28% | -18.25 | 0 Comment | |
| DeathStock | 52.79 | 1/28/2019 |
|
5Y | $15.95 | -36.61% | +13.70% | -50.31 | 0 Comment | |
| gunda7907 | < 20 | 1/17/2019 |
|
5Y | $16.90 | -40.16% | +14.29% | -54.45 | 0 Comment | |
| shanelofgren | 31.35 | 1/2/2019 |
|
5Y | $17.02 | -40.58% | +19.39% | -59.98 | 1 Comment | |
| Reallynow222 | 97.48 | 11/19/2018 |
|
5Y | $21.63 | -53.26% | +9.87% | -63.13 | 0 Comment | |
| adasand | 48.64 | 7/18/2018 |
|
5Y | $30.57 | -66.93% | +6.55% | -73.48 | 0 Comment | |
| jack0071 | 69.51 | 11/27/2017 |
|
5Y | $24.80 | -59.23% | +14.84% | -74.07 | 0 Comment | |
| portefeuille7 | 91.37 | 5/21/2018 |
|
5Y | $29.50 | -65.73% | +9.50% | -75.23 | 0 Comment | |
| portefeuille9 | 93.81 | 5/21/2018 |
|
5Y | $29.50 | -65.73% | +9.50% | -75.23 | 0 Comment | |
| portefeuille10 | 97.51 | 5/21/2018 |
|
5Y | $29.50 | -65.73% | +9.50% | -75.23 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
| Player Name | Player Rating |
Start Date |
Call | Time Frame |
Start Price |
Stock Gain |
S&P Gain |
Score | End Date | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| TrackJimCramer | 86.41 | 12/22/2015 |
|
3W | $29.05 | -65.20% | +46.90% | -112.10 | 0 Comment |
